TOKYO, Japan & BASKING RIDGE, NJ, USA I June 09, 2025 I
The first patient has been dosed in the
DESTINY-Endometrial01
phase 3 trial evaluating ENHERTU
®
(trastuzumab deruxtecan) in combination with rilvegostomig or pembrolizumab versus platinum-based chemotherapy (carboplatin and paclitaxel) in combination with pembrolizumab as a first-line therapy in patients with HER2 expressing (IHC 3+/ 2+), mismatch repair proficient (pMMR) primary advanced or recurrent endometrial cancer. DESTINY-Endometrial01 will be conducted in collaboration with The GOG Foundation, Inc. (GOG-F) and the European Network of Gynecological Oncological Trial (ENGOT).
ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN).
Endometrial cancer that is recurrent or diagnosed in advanced stages has a median overall survival of up to 30 months.
1
While there have been recent treatment advances, there is still a need to further improve outcomes for patients. HER2 expression (IHC 3+/2+) is associated with aggressive disease and is present in 18% to 56% of endometrial cancers.
2,3,4,5,6
There currently are no HER2 directed medicines approved in the first-line endometrial cancer setting.
“Following the positive results in the endometrial cancer cohort of DESTINY-PanTumor02, which contributed to a tumor agnostic approval for previously treated patients with HER2 positive metastatic tumors in several regions, we are initiating this first phase 3 trial of ENHERTU in the first-line setting of advanced endometrial cancer,” said Mark Rutstein, MD, Head, Therapeutic Area Oncology Development, Daiichi Sankyo. “The DESTINY-Endometrial01 trial will help us better understand the role of ENHERTU in combination with immunotherapy as a potential treatment strategy to help improve outcomes compared to the current standard of care in this specific gynecological cancer setting.”
About DESTINY-Endometrial01
DESTINY-Endometrial01
is a global, multicenter, randomized, open-label phase 3 trial evaluating the efficacy and safety of ENHERTU (5.4 mg/kg) in combination with rilvegostomig or pembrolizumab versus platinum-based chemotherapy (carboplatin and paclitaxel) in combination with pembrolizumab as a first-line therapy in patients with HER2 expressing (IHC 3+/2+), pMMR, primary advanced (stage III/IV) or first recurrent endometrial cancer of any histologic subtype except sarcoma. Patients will be randomized in a 1:1:1 ratio to receive either ENHERTU in combination with rilvegostomig, ENHERTU in combination with pembrolizumab or platinum-based chemotherapy in combination with pembrolizumab.
The primary endpoint is progression-free survival (PFS) as assessed by blinded independent central review (BICR). The key secondary endpoint is overall survival. Additional secondary endpoints include PFS as assessed by investigator, objective response rate, duration of response and safety.
DESTINY-Endometrial01 will enroll approximately 600 patients across multiple sites in Asia, Europe, North America, Oceania and South America. For more information about the trial, visit
ClinicalTrials.gov
.
Rilvegostomig is AstraZeneca’s PD-1/TIGIT bispecific antibody. The TIGIT component of rilvegostomig is derived from the clinical-stage anti-TIGIT antibody, COM902, developed by Compugen Ltd. (Nasdaq/TASE: CGEN). Pembrolizumab (KEYTRUDA
®
) is Merck’s (known as MSD outside of the US and Canada) anti-PD-1 therapy.
About Endometrial Cancer
Endometrial cancer is the second most common gynecologic cancer and the sixth most common cancer among women worldwide.
7
Approximately 420,000 endometrial cancer cases were diagnosed in 2022, with more than 97,000 deaths globally.
8
Incidence and mortality rates of endometrial cancer are expected to increase by approximately 61% and 87% respectively by 2050.
9
Patients with advanced or recurrent endometrial cancer have a poor prognosis, with a median overall survival of up to 30 months.
1
Endometrial cancer comprises several molecular subtypes.
10
Approximately 20% to 30% of all endometrial cancers exhibit high microsatellite instability (MSI) due to a defective mismatch repair system and are classified as MSI-high or MMR deficient (dMMR).
10
The remaining 70% to 80% of cases are considered mismatch repair proficient (pMMR) tumors.
10
HER2 is a tyrosine kinase receptor growth-promoting protein expressed on the surface of many types of tumors.
11
HER2 expression (IHC 3+/ 2+) is present in 18% to 56% of endometrial cancers and is associated with markers of aggressive disease.
2,3,4,5,6
HER2 expression is observed almost exclusively in pMMR tumors.
2
Standard of care first-line treatment of advanced or recurrent endometrial cancer has long included carboplatin plus paclitaxel.
12
The treatment paradigm has recently evolved to incorporate an immune checkpoint inhibitor with carboplatin and paclitaxel, particularly for patients with dMMR endometrial cancer; however, the benefit of this treatment regimen in pMMR endometrial cancer is less pronounced.
13,14,15,16
There currently are no HER2 directed medicines approved in the first-line endometrial cancer setting.
About ENHERTU
ENHERTU (trastuzumab deruxtecan; fam-trastuzumab deruxtecan-nxki in the U.S. only) is a HER2 directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC Technology, ENHERTU is the lead ADC in the oncology portfolio of Daiichi Sankyo and the most advanced program in AstraZeneca’s ADC scientific platform. ENHERTU consists of a HER2 monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers.
ENHERTU (5.4 mg/kg) is approved in more than 80 countries worldwide for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization (ISH)+) breast cancer who have received a prior anti-HER2-based regimen, either in the metastatic setting or in the neoadjuvant or adjuvant setting, and have developed disease recurrence during or within six months of completing therapy based on the results from the
DESTINY-Breast03
trial.
ENHERTU (5.4 mg/kg) is approved in more than 80 countries worldwide for the treatment of adult patients with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy based on the results from the
DESTINY-Breast04
trial.
ENHERTU (5.4 mg/kg) is approved in more than 30 countries for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 low (IHC 1+ or IHC 2+/ISH-) or HER2 ultralow (IHC 0 with membrane staining) breast cancer, as determined by a locally or regionally approved test, that has progressed on one or more endocrine therapies in the metastatic setting based on the results from the
DESTINY-Breast06
trial.
ENHERTU (5.4 mg/kg) is approved in more than 60 countries worldwide for the treatment of adult patients with unresectable or metastatic NSCLC whose tumors have activating
HER2
(
ERBB2
) mutations, as detected by a locally or regionally approved test, and who have received a prior systemic therapy based on the results from the
DESTINY-Lung02
and/or
DESTINY-Lung05
trials. Continued approval in China and the U.S. for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
ENHERTU (6.4 mg/kg) is approved in more than 70 countries worldwide for the treatment of adult patients with locally advanced or metastatic HER2 positive (IHC 3+ or IHC 2+/ISH+) gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen based on the results from the
DESTINY-Gastric01
,
DESTINY-Gastric02
and/or
DESTINY-Gastric06
trials. Continued approval in China for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
ENHERTU (5.4 mg/kg) is approved in Brazil, Israel, Russia, Saudi Arabia, Switzerland, Taiwan, U.K. and the U.S. for the treatment of adult patients with unresectable or metastatic HER2 positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options based on efficacy results from the
DESTINY-PanTumor02
,
DESTINY-Lung01
and
DESTINY-CRC02
trials. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
About the ENHERTU Clinical Development Program
A comprehensive global clinical development program is underway evaluating the efficacy and safety of ENHERTU as a monotherapy or in combination or sequentially with other anti-cancer therapies across multiple HER2 targetable cancers.
About the Daiichi Sankyo and AstraZeneca Collaboration
Daiichi Sankyo and AstraZeneca entered into a global collaboration to jointly develop and commercialize ENHERTU in
March 2019
and DATROWAY
®
in
July 2020
, except in Japan where Daiichi Sankyo maintains exclusive rights for each ADC. Daiichi Sankyo is responsible for the manufacturing and supply of ENHERTU and DATROWAY.
About the ADC Portfolio of Daiichi Sankyo
The Daiichi Sankyo ADC portfolio consists of seven ADCs in clinical development crafted from two distinct ADC technology platforms discovered in-house by Daiichi Sankyo.
The ADC platform furthest in clinical development is Daiichi Sankyo’s DXd ADC Technology where each ADC consists of a monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers. The DXd ADC portfolio currently consists of ENHERTU, a HER2 directed ADC, and DATROWAY, a TROP2 directed ADC, which are being jointly developed and commercialized globally with AstraZeneca. Patritumab deruxtecan (HER3-DXd), a HER3 directed ADC, ifinatamab deruxtecan (I-DXd), a B7-H3 directed ADC, and raludotatug deruxtecan (R-DXd), a CDH6 directed ADC, are being jointly developed and commercialized globally with Merck & Co., Inc, Rahway, NJ, USA. DS-3939, a TA-MUC1 directed ADC, is being developed by Daiichi Sankyo.
The second Daiichi Sankyo ADC platform consists of a monoclonal antibody attached to a modified pyrrolobenzodiazepine (PBD) payload. DS-9606, a CLDN6 directed PBD ADC, is the first of several planned ADCs in clinical development utilizing this platform.
Ifinatamab deruxtecan, patritumab deruxtecan, raludotatug deruxtecan, DS-3939 and DS-9606 are investigational medicines that have not been approved for any indication in any country. Safety and efficacy have not been established.
Please see accompanying full
Prescribing Information
, including Boxed WARNINGS, and
Medication Guide
.
About Daiichi Sankyo
Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need. For more information, please visit
www.daiichisankyo.com
.
References
1
Coleman RL, et al.
JHEOR
.2023;10(2):82-90.
2
Vermij L, et al.
Cancers (Basel)
.
2020;13(1):44.
3
Buza N.
Arch Pathol Lab Med
.
2021;145(6):687–691.
4
Uzunparmaek B, et al.
Ann Oncol
.
2023;34(11):1035-1046.
5
Semiz SH, et al.
Turkish Journal of Pathology
.2023;39(1):055-063
6
Halle MK, et al.
Br J Cancer
.
2017;118(3):378-387.
7
GLOBOCAN.
International agency for research on cancer (IARC): Age-Standardized Rate (World) per 100 000, Incidence and Mortality, Females, all ages in 2022
.
Accessed June 2025.
8
GLOBOCAN.
Uterine Cancer Fact Sheet
.
Accessed June 2025.
9
World Health Organization. Cancer Tomorrow: Corpus Uteri. Accessed June 2025.
10
Corr B, et al.
BMJ Med
. 2022;1:e000152.
11
Omar N, et al.
Pathogenesis
. 2015 2(3):1-9.
12
Miller DS, et al.
J Clin Oncol
. 2020;38:3841–3850.
13
Mirza MR, et al.
N Engl J Med
. 2023:8;388:2145–2158.
14
Eskander RN, et al.
N Engl J Med
. 2023;388:2159–2170.
15
Westin SN, et al.
J Clin Oncol
. 2024;42:283–299.
16
Colombo N, et al.
Lancet Oncol
. 2024;25:1135–1146.
SOURCE:
Daiichi Sankyo
